Clinicians should evaluate for possible pregnancy before initiation of treatment. Obtaining vitamin D levels and clearance from a dentist is suggested before initiating therapy. Within the first few weeks of treatment, recommended monitoring of serum creatinine, calcium, phosphorus, and magnesium. Monitor for signs and symptoms of hypocalcemia as well as hypercalcemia upon discontinuation of denosumab.